Christopher James Bergeron

US Patent:

20220362311, Nov 17, 2022

Filed:

Jun 19, 2020

Appl. No.:

17/621121

Inventors:

- Cambridge MA, US
- Boston MA, US
Philippa Jane Reeder Morrison - Arlington MA, US
Christopher George Bergeron - Fitchburg MA, US
Dylan Alexander Carlin - Jamaica Plain MA, US
Laura K. Stone - Cambridge MA, US
Alex C. Tucker - Dorchester MA, US
Patrick M. Boyle - Boston MA, US

International Classification:

A61K 35/747
A61K 35/741
A61K 35/745
A61K 35/742
A61K 35/744
A61P 13/02
C12N 1/20
C12N 15/52
C12N 15/70

Abstract:

The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patients internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding an improved leucine catabolism enzyme with higher activity and/or specificity for leucine over other branched chain amino acids, such as isoleucine or valine. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of leucine, isoleucine, and/or valine using the pharmaceutical compositions disclosed herein.

US Patent:

20230105474, Apr 6, 2023

Filed:

Feb 25, 2021

Appl. No.:

17/801854

Inventors:

- Cambridge MA, US
Sean Cotton - Somerville MA, US
Jian-Rong Gao - Malden MA, US
Teodelinda Mirabella - Boston MA, US
Christopher George Bergeron - Fitchburg MA, US

International Classification:

A61K 35/74
C12N 15/63
C12N 9/06
C12N 15/70
A61K 38/44
A61P 19/06

Abstract:

The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells that comprise a uric acid catabolism enzyme, e.g., a uric acid degrading enzyme, for the treatment of diseases and disorders associated with uric acid, including hyperuricemia and gout, in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with uric acid, such as hyperuricemia.